Development of Lipid-based Nano Formulations of Miriplatin against Lung Cancer

Lung cancer claims the highest mortality and the second most new cases in the US. Cisplatin, the first platinum-based anticancer drug, has the highest potency against lung cancer but carries many severe adverse effects. Miriplatin was discovered with a higher lipophilicity and approved in Japan for the treatment of hepatocellular carcinoma (HCC). Nanocarriers provide a promising platform to overcome the physiochemical barrier of solid tumors and to reduce the toxicity of anticancer drugs